Active substance
Tetracycline
- SFDA 13
- US FDA 54
- Health Canada 1
- US price lines 2
- NHS prices 1
- WHO EML 1
- Safety 3
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| OPTICYCLIN 1 % OINTMENT | 1 % | Ointment · Ophthalmic use | 1 Tube | SAR 3.00 | Generic · Prescription | Amman Pharmaceutical Industries (API) | Valid |
| TETRACYCLINE SKIN OINT 3% | 3 % | Ointment · Topical | 1 Tube | SAR 3.00 | NCE · Prescription | Gulf Pharmaceutical Industries (Julphar) | Valid |
| BALKACYCLINE 250MG CAP | 250 mg | Capsule · Oral use | 20 Blister | SAR 6.00 | Generic · Prescription | APM | Withdrawn by MAH · Not Marketed |
| DUMOCYCLIN 1.M.VIAL | 100 mg | Solution · Intramuscular use | 6 Vial | SAR 32.90 | NCE · Prescription | XELLIA PHARMACEUTICAL APS | Withdrawn by MAH · Not Marketed |
| DUMOCYCLIN 250 MG CAP | 250 mg | Capsule · Oral use | 16 Blister | SAR 15.10 | NCE · Prescription | XELLIA PHARMACEUTICAL APS | Withdrawn by MAH · Not Marketed |
| DUMOCYCLINE 500MG INJ | 500 mg | Solution for injection · Intravenous use | 1 Vial | SAR 6.70 | NCE · Prescription | XELLIA PHARMACEUTICAL APS | Withdrawn by MAH · Not Marketed |
| DUMOCYCLINE EYE OINT | 1 % | Ointment · Ophthalmic use | 1 Tube | SAR 3.65 | NCE · Prescription | XELLIA PHARMACEUTICAL APS | Withdrawn by MAH · Not Marketed |
| LATYCIN E-E OINT 1% | 1 % | Ear/eye ointment · Ocular use | 5 Tube | SAR 4.60 | NCE · Prescription | SANDOZ | Withdrawn by MAH · Not Marketed |
| TERACIN | 1 % | Eye ointment · Ocular use | 1 Tube | SAR 3.70 | Generic · Prescription | RIYADH PHARMA | Withdrawn by MAH · Not Marketed |
| TERRAMYCIN CAPS 250MG | 250 mg | Capsule · Oral use | 16 Blister | SAR 21.00 | Generic · Prescription | PFIZER | Withdrawn by MAH · Not Marketed |
| TETRACYCLIN 250MG CAPS | 250 mg | Capsule · Oral use | 24 Blister | SAR 13.60 | Generic · Prescription | Gulf Pharmaceutical Industries (Julphar) | Withdrawn by MAH · Not Marketed |
| TETRACYCLINE 500MG CAPS | 500 mg | Capsule · Oral use | 12 Blister | SAR 12.50 | Generic · Prescription | Gulf Pharmaceutical Industries (Julphar) | Withdrawn by MAH · Not Marketed |
| TETRADAR 250 MG CAP | 250 mg | Capsule · Oral use | 16 Blister | SAR 1.80 | Generic · Prescription | DAR ALDAWA | Withdrawn by MAH · Not Marketed |
Indications — CHI Daman Drug Formulary
MUCOPURULENT CONJUCTIVITIS - GONOCOCCAL INFECTION OF THE EYE - CHLAMYDIAL CONJUNCTIVITIS
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| ACHROMYCIN V | 500MG; 250MG | capsule · oral | AVET | Prescription | 8 Oct 1957 |
| SUMYCIN | 250MG; 500MG | tablet · oral | STRIDES PHARMA INTL | Prescription | 10 Feb 1971 |
| TETRACYCLINE HYDROCHLORIDE | 250MG; 500MG | capsule · oral | WATSON LABS | Prescription | 24 Dec 1974 |
| TETRACYCLINE HYDROCHLORIDE | 250MG; 500MG | capsule · oral | CHARTWELL TETRA | Prescription | 12 Aug 1988 |
| TETRACYCLINE HYDROCHLORIDE | 250MG; 500MG | capsule · oral | AMNEAL PHARMS NY | Prescription | 18 Sep 2018 |
| TETRACYCLINE HYDROCHLORIDE | 250MG; 500MG | capsule · oral | BRECKENRIDGE | Prescription | 7 Nov 2018 |
| TETRACYCLINE HYDROCHLORIDE | 250MG; 500MG | capsule · oral | NOVITIUM PHARMA | Prescription | 3 Mar 2020 |
| ACHROMYCIN | 250MG/VIAL; 500MG/VIAL | injectable · injection | LEDERLE | Discontinued | 19 Nov 1953 |
| SUMYCIN | 250MG; 100MG; 500MG; 125MG | capsule · oral | APOTHECON | Discontinued | 17 Sep 1954 |
| PANMYCIN | 250MG | capsule · oral | PHARMACIA AND UPJOHN | Discontinued | 28 Sep 1954 |
| ACHROMYCIN V | 125MG/5ML | suspension · oral | LEDERLE | Discontinued | 27 Jan 1955 |
| TETRACYN | 125MG/5ML | suspension · oral | PFIPHARMECS | Discontinued | 2 Sep 1955 |
| ACHROMYCIN | 1% | suspension/drops · ophthalmic | STORZ | Discontinued | 23 Nov 1955 |
| ACHROMYCIN | 10MG/GM | ointment · ophthalmic | STORZ | Discontinued | 19 Apr 1957 |
| SUMYCIN | 125MG/5ML | suspension · oral | PH HEALTH | Discontinued | 21 Jun 1957 |
| TETRACYCLINE HYDROCHLORIDE | 250MG; 500MG | capsule · oral | IVAX SUB TEVA PHARMS | Discontinued | 5 Jul 1963 |
| TETRACYCLINE HYDROCHLORIDE | 125MG/5ML | suspension · oral | FERRANTE | Discontinued | 22 Oct 1964 |
| TETRACYCLINE HYDROCHLORIDE | 125MG; 250MG | capsule · oral | FERRANTE | Discontinued | 19 Nov 1964 |
| TETRACYCLINE HYDROCHLORIDE | 250MG; 500MG | capsule · oral | AUROBINDO PHARMA USA | Discontinued | 17 Jul 1968 |
| SUMYCIN | 100MG; 50MG | tablet · oral | STRIDES PHARMA INTL | Discontinued | 10 Feb 1971 |
| TETRACYCLINE HYDROCHLORIDE | 250MG; 100MG; 500MG | capsule · oral | IMPAX LABS | Discontinued | 13 Jul 1971 |
| TETRACYCLINE HYDROCHLORIDE | 500MG | capsule · oral | ROXANE | Discontinued | 22 May 1972 |
| BRISTACYCLINE | 250MG; 500MG | capsule · oral | BRISTOL | Discontinued | 28 Jun 1972 |
| CYCLOPAR | 250MG; 500MG | capsule · oral | WARNER CHILCOTT | Discontinued | 8 Jun 1973 |
| BRISTACYCLINE | 250MG; 500MG | capsule · oral | BRISTOL | Discontinued | 5 Dec 1974 |
29 more — full table
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| TETRACYCLINE | 00580929 | 250 MG | CAPSULE · ORAL | AA PHARMA INC |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | TETRACYCLINE 250 MG CAPSULE | $0.24722 | per EA | 23 Sep 2026 |
| US NADAC | TETRACYCLINE 500 MG CAPSULE | $0.62654 | per EA | 23 Sep 2026 |
| NHS Drug Tariff | Tetracycline 250mg tablets | £45.02 | 28 tablet | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
WHO WHO Model List of Essential Medicines (2025)
- 21.1. Ophthalmological preparations > Anti-infective agents · core
Other specified conjunctivitis; Infectious keratitis; Infectious blepharitis; Trachoma
Local > Ophthalmological > Ointment: 1% (tetracycline hydrochloride)
Safety signals and safety-related labeling changes
- US FDA 31 Mar 2025 HELIDAC — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions - US FDA 31 Mar 2025 PYLERA — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 31 Mar 2025 ACHROMYCIN V — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.